Hypersensitivity reactions to trimetrexate

UMMS Affiliation

Department of Medicine, Division of Hematology/Oncology



Document Type



Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Drug Hypersensitivity; Female; Folic Acid Antagonists; Humans; Infusions, Intravenous; Male; Middle Aged; Quinazolines; Trimetrexate


Life Sciences | Medicine and Health Sciences | Women's Studies


Trimetrexate is a nonclassical antifol currently being tested for efficacy in cancer patients and as an antiparasitic agent against Pneumocystis carinii pneumonia in AIDS patients. We have now received the first reports of hypersensitivity reactions in Phase II cancer trials. Two types of reactions were noted. The most severe reaction, immediate hypotension with loss of consciousness, occurred in only one patient. Four other patients exhibited an immediate systemic effect with one or more of the following symptoms: facial flushing, fever, shaking, pruritus, bronchospasm, periorbital edema, and difficulty in swallowing. Immediate hypersensitivity should now be considered a known side effect of trimetrexate therapy, occurring in less than 2% of patients.

Rights and Permissions

Citation: Invest New Drugs. 1990 May;8(2):211-4.

Related Resources

Link to article in PubMed

PubMed ID